title: Efficacy of two different platinum- or anthracycline-containing chemotherapy regimens for the treatment of small cell lung cancer.
abstract: The records of 190 consecutive patients referred to our department to be treated for small cell lung cancer were retrospectively evaluated, and the outcomes were compared on the basis of their first-line treatment. 113 patients were treated with 4-6 courses of cyclophosphamide, epidoxorubicin and etoposide (CEVP16), 77 with 4-6 courses of carboplatin and etoposide (CBE). 72 patients had limited disease and 118 extensive disease. Response rates were 58.4% for CEVP16 and 28.6% for CBE (p=0.0001), with no significant difference in the time to progression (255 vs 246 days, p=0.21). Overall survival was 334 days and 212 days, and the 1-year survival rate was 46% and 22.1%, respectively (p=0.0018). In patients with limited disease, overall survival was 434 days and 249 days (p=0.08) in both treatment group respectively and 281 and 208 days in those with extensive disease, respectively (p=0.02). No difference in side effects was observed between the two groups of patients. Our data suggest a role for anthracycline-containing regimens as first-line treatment of small cell lung cancer.
authors.affiliation: Department of Oncology, City Hospital, viale Settembrini n. 2, 47900, Rimini, Italy. dtassinari@rimini.com
authors.forename: D
authors.initials: D
authors.lastname: Tassinari
authors.forename: G
authors.initials: G
authors.lastname: Genestreti
authors.forename: E
authors.initials: E
authors.lastname: Pasquini
authors.forename: M
authors.initials: M
authors.lastname: Papi
authors.forename: M
authors.initials: M
authors.lastname: Fantini
authors.forename: E
authors.initials: E
authors.lastname: Tamburini
authors.forename: F
authors.initials: F
authors.lastname: Fochessati
authors.forename: B
authors.initials: B
authors.lastname: Poggi
authors.forename: M
authors.initials: M
authors.lastname: Imola
authors.forename: A M
authors.initials: AM
authors.lastname: Mianulli
authors.forename: P P
authors.initials: PP
authors.lastname: Fattori
authors.forename: L
authors.initials: L
authors.lastname: Lazzari-Agli
authors.forename: G
authors.initials: G
authors.lastname: Ioli
authors.forename: S
authors.initials: S
authors.lastname: Sartori
authors.forename: A
authors.initials: A
authors.lastname: Ravaioli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D016009:Chi-Square Distribution; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011336:Probability; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D015251:Epirubicin; D005047:Etoposide; D016190:Carboplatin